CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
DerMend Moisturizing Bruise Formula +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01910831
NCT01910831Phase 4Completed
CompareCT.gov

Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands

The Center for Clinical and Cosmetic Research·interventional·Posted Jul 30, 2013·Updated Dec 2, 2019

In Brief

A Phase 4 clinical trial evaluating DerMend Moisturizing Bruise Formula and Non-active placebo control for Purpura. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To determine the efficacy (measured at 12 weeks) of DerMend Moisturizing Bruise Formula in improving the appearance of bruising and reducing the appearance of photoaging of the forearms and hands in mature skin. Assessments will be made through ongoing objective measurements and clinical ratings. To confirm the safety (local tolerance) of DerMend Moisturizing Bruise Formula.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPurpura
CountriesUnited States
CollaboratorsFerndale Laboratories, Inc.

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 30, 2013
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.9 years ago

Interventions

DerMend Moisturizing Bruise Formuladrug

DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.

Non-active placebo controldrug

Non-active placebo control